ANTIVIRAL COMPOUND AND COX-2 INHIBITOR COMBINATION THERAPY FOR FIBROMYALGIA

(19)

(11)

EP 2 965 759 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	11.03.2020 Bulletin 2020/11

(45)	Mention of the grant of the patent:
	30.10.2019 Bulletin 2019/44

(21)	Application number: 15179077.1

(22)	Date of filing: 06.02.2013

(51)

International Patent Classification (IPC):

A61K 31/415^(2006.01)
A61K 45/06^(2006.01)
A61P 1/00^(2006.01)
A61K 31/5575^(2006.01)
A61K 31/522^(2006.01)
A61K 31/427^(2006.01)

A61K 31/52^(2006.01)
A61P 29/00^(2006.01)
A61P 25/00^(2006.01)
A61K 31/196^(2006.01)
A61K 31/5415^(2006.01)

(54)	ANTIVIRAL COMPOUND AND COX-2 INHIBITOR COMBINATION THERAPY FOR FIBROMYALGIA ANTIVIRALE VERBINDUNG UND COX-2-INHIBITOR-KOMBINATIONSTHERAPIE FÜR FYBROMYALGIE COMPOSÉ ANTI-VIRAL ET THÉRAPIE À COMBINAISON D'INHIBITEUR COX-2 POUR LA FIBROMYALGIE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

06.02.2012 US 201261595507 P

(43)	Date of publication of application:
	13.01.2016 Bulletin 2016/02

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	13746016.8 / 2811833

(73)	Proprietor: Innovative Med Concepts, LLC
	Tuscaloosa, AL 35406 (US)

(72)	Inventor:
	Pridgen, William L. Tuscaloosa, AL 35406 (US)

(74)	Representative: Haseltine Lake Kempner LLP
	Redcliff Quay 120 Redcliff Street Bristol BS1 6HU Bristol BS1 6HU (GB)

(56)

References cited: :

JP-A- 2008 260 728
US-A1- 2002 037 501
US-A1- 2004 072 144
US-A1- 2005 119 194

US-A- 5 559 114
US-A1- 2004 030 151
US-A1- 2004 229 038
US-A1- 2010 222 289

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).